Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 186 for “"HER2 Positive"”.
-
Metabolic vulnerability in HER2-positive Breast Cancer
… human epidermal growth factor receptor 2, or HER2, is overexpressed in 20-30% breast cancer patients and is associated with aggressive disease. Therapies targeting HER2, including monoclonal antibodies (trastuzumab and pertuzumab), a small molecule kinase inhibitor (lapatinib) and an …
-
Role Of MIR-489 In HER2 Positive Breast Cancer
Human epidermal growth factor receptor 2 (HER2 or ErBb2) is a receptor tyrosine kinase overexpressed in 20-30% of breast cancers and associated with poor prognosis and outcome. Dysregulation of several micro RNAs (miRs) plays a key role in breast cancer progression and metastasis. In this study, we …
-
Identification of microRNA Biomarkers in HER2-Positive Breast Cancer
Human epidermal growth factor receptor 2 (HER2) is overexpressed in approximately 30% of breast cancer patients with poor prognosis. In addition, microRNAs are small non-coding RNA that have been linked to many cancers. Here we investigate which miRNAs are differentially regulated by HER2 …
-
Factors affecting treatment choice in HER2 positive metastatic breast cancer.
Women with HER2 positive breast cancer have decreased overall survival and may have a poorer response to treatment. Evidence suggests that disparities exist in treatment and outcomes in individuals with diverse racial and ethnic backgrounds, the elderly, individuals that are obese, hormone receptor …
-
Gut Microbiota and Trastuzumab Response in HER2- Positive Breast Cancer
The use of trastuzumab as standard treatment for HER2-positive breast carcinomas (BCs) had largely improved the clinical outcome of BCs patients. Unfortunately, many of them do not respond to the therapy and the pathological complete response (pCR) is achieved in only 50% of patients even in those …
-
BAG-1 expression and function in HER2-positive breast cancer
… Human epidermal growth factor receptor 2 (HER2/ neu) is overexpressed in 15- 25% of breast cancer and is a marker of poor prognosis. Treatment with the monoclonal antibody trastuzumab (Herceptin™) can reduce the risk of death by a third and halve the risk of recurrence, but many of those …
-
Mechanisms of resistance to lapatinib in HER2 positive breast cancer
Lapatinib is a tyrosine kinase inhibitor of HER2 which blocks downstream signaling pathways in HER2 positive breast cancer cell lines, tumor xenografts and HER2 positive breast cancer patients. However, pre-clinical and clinical studies have shown that HER2 positive patients can exhibit either …
-
Resistance to HER2-targeted therapies in HER2-positive breast cancer
… and human epidermal growth factor receptor 2 (HER2). Historically, HER2-positive breast cancers had a worse survival prognosis than oestrogen or progesterone receptor-positive cancers, but the development of HER2-targeted therapies led to significant survival improvements. Despite this, …
-
Targeting telomerase in HER2 positive breast cancer: role of cancer stem cells
… The Human Epidermal growth factor Receptor 2 (HER2) gene is amplified and/or its protein product overexpressed in approximately 20% of breast cancers. HER2 overexpression is associated with increased CSCs, which may explain the aggressive phenotype and increased likelihood of recurrence for …
-
Targeted chemotherapy: Trastuzumab tailored Docetaxel loaded PLGA nanoaparticles for HER2 positive breast cancer
… (NPs) to target the human epidermal receptor-2 (HER2) receptors of breast cancer cells. Utilizing emulsification solvent evaporation technique, pre-activated drug loaded NPs were prepared by embedding a homo bi-functional spacer, bis(sulfosuccinimidyl) suberate (BS3) non-covalently onto the NP …
-
Development and Evaluation of Novel Anti-HER2 Theranostics Against HER2-Positive Breast Cancer
… rates. Human epidermal growth factor receptor 2 (HER2) is overexpressed in 20-30% of BC. HER2 overexpression is also observed in other cancers such as gastric/gastroesophageal, ovarian, lung, prostate, bladder, colon and head and neck. HER2-positive BC is characterized by aggressive disease and …
-
Development of a novel plant expressed conjugate vaccine for HER2-positive breast cancer
Overexpression HER2/neu correlates with poor prognosis in many cancers, including breast cancer. HER2-specific monoclonal antibodies including Herceptin® have had significant impact on breast cancer survival rates. However, there are a number of limitations with their use, including tumour …
-
99MTC-RADIOLABELED NANOPARTICLES FOR TARGETED DETECTION AND TREATMENT OF HER2-POSITIVE BREAST CANCER
Introduction: The HER2 receptor overexpression is normally associated to aggressive and infiltrating breast cancer (BC) phenotype with propensity to spread into metastases. Nowadays, the detection of HER2 in primary tumor lesions and in their metastases is based on invasive methods as well therapy …
-
The role of the Fer protein-tyrosine kinase in HER2-positive breast cancer
… Interestingly, in a transgenic mouse model of HER2-positive breast cancer, mice targeted with a kinase-inactivating mutation (ferDR/DR) had delayed tumor onset, suggesting an important role for Fer activity in tumorigenesis. ferDR/DR mammary tumor epithelial cells (MTECs) from these tumors were …
-
Longitudinal T cell receptor repertoire analysis in immunotherapy of HER2-positive breast cancer
… women. Certain subtypes of breast cancer, like HER2-positive breast cancer overexpressing the receptor HER2, are treated using neoadjuvant immunochemotherapy containing anti-HER2 antibodies. T cells are immune cells identified by a T cell receptor, which is capable of highly specific binding to …
-
The Ontogeny and Vulnerability of Lapatinib Drug Tolerant Persisters in HER2-positive Breast Cancer
HER2-positive breast cancer accounts for 15-20% of all breast cancer cases. Early-stage HER2-positive breast cancer is typically curable with surgery and trastuzumab/chemotherapy combinations, but most metastatic HER2-positive breast cancer inevitably recurs following treatment. Drug-tolerant …
-
Jab1 Negatively Regulates Pten and Promotes Resistance to Trastuzumab In Her2-Positive Breast Cancer
HER2-positive breast cancer, which is characterized by the over-expression of the HER2 onco-protein, accounts for approximately 20% of all breast cancer cases. Trastuzumab (Herceptin), the first targeted therapy approved for HER2-positive disease, potently prevents the activation of signaling …
-
The Effect of Sox9 on Cell Growth and Stemness in HER2-Positive Breast Cancer
… and its incidence increases each year. The HER2-positive subtype is associated with aggressive disease and poor outcome, with a high risk of acquired resistance to first-line treatment. A key contributor to these qualities is epithelial-to-mesenchymal transition (EMT). Sox9 has been linked …
-
Targeting HER2-positive cell lines by transmembrane peptide based surface-active ionic liquid nanoformulation
Human epidermal growth factor receptor 2 (HER2/ErbB2) is a major oncogenic driver in many cancers, and its extracellular or intracellular domains are the main therapeutic targets. In contrast, the transmembrane domain (TMD), which also plays an important role in receptor dimerization and …
Page 1 of 10